People news

Share this article:

People news
MANUFACTURERS

Wyeth announced the promotion of Wendy Kouba to VP, corporate communications, Wyeth. Kouba will oversee the company's global public relations and communications functions including issues management, media relations, product publicity, internal communications, community relations and corporate contributions. Kouba joined Wyeth in September 2006 and was most recently VP, communications, technical operations & product supply (TO&PS), with responsibility for all internal and external communications and issues management across the global TO&PS network. Prior to joining the company, Kouba held leadership roles directing internal and external communications, issues management, executive communications, brand positioning and organizational effectiveness initiatives at Johnson & Johnson, Pharmacia, JPMorgan Chase and AlliedSignal.

AGENCIES
Concentric Pharma Advertising has hired Ken Moran as director of agency operations. Moran, reports to Ken Begasse Jr., director of client services. In his new position, Moran, will oversee Concentric's project management, editorial, studio and production departments. Prior to joining Concentric, Moran was creative project director at GSW Worldwide in Westerville, OH, managing accounts and monitoring traffic, processes and budgets.  Before that he was traffic director at Cline Davis & Mann in New York.

SUPPLIERS
TNS Healthcare announced two new appointments, Larry Olson, who will serve as VP, practice leader, payer markets, and Dennis Callahan, who will serve as VP, sales force effectiveness.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.